Biomarkers have moved from “nice-to-have” to the backbone of drug development, says Quanterix’s Jorge Marques Signes, who argues they now shape feasibility, timelines and even payer expectations before sponsors commit thousands of patients or years of spend. “Biomarkers are not supplemental anymore,” said Marques Signes, VP of Accelerator & Clinical Services at Quanterix. “They are…
The quest for a disease-modifying drug for Parkinson’s disease continues
The need for therapies that change the course of Parkinson’s disease is considerable. “There are zero disease-modifying treatments for Parkinson’s,” said Dr. Allan Levey, professor and chairman of Emory University’s department of neurology. Parkinson’s disease affects some 10 million people worldwide, according to the Parkinson’s Foundation. Current drugs for Parkinson’s make it possible to “reverse…